| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e3830f35387a1c32061dea3ee310851 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-124
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-20 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0647
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0775
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M37-00 |
| filingDate |
2011-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6a3efd15f43abcdd9f2ad5625b6337c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a2969340ecd1de1906580e01eff6936 |
| publicationDate |
2011-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011251593-A1 |
| titleOfInvention |
In Vivo and Ex Vivo Expansion of Hematopoietic Stem Cells With a Targeted Combination of Clinically Tested, FDA Approved Drugs |
| abstract |
The present invention provides a therapeutic approach to maintain and expand HSCs in vivo using currently available medications that target GSK-3 and mTOR. The present invention also provides a system and method for the ex vivo culturing of HSCs, where an mTOR inhibitor is combined with a GSK-3 inhibitor within the culturing conditions. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2999343-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11261429-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113684180-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105705021-A |
| priorityDate |
2010-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |